Biologics Pipelines: Who Has the Next Promising Monoclonal Antibodies?Decision ResourcesMarch 18, 2008 39 Pages - SKU: DECR1725816 |
|
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
5/11/2012 | published by: Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a
|
more...
|
$3,995.00
|
|
541711 Research and Development In Biotechnology: State Industry Market Evaluator
6/1/2012 | published by: BizMiner
This State Industry Market Evaluator reports on industry trends broken out for each US state. Each state sub-report is comprised of eight pages of data. Statistics are displayed for 2008-2009-2010 and 2011q2 for these measures:
|
more...
|
$699.00
|
|
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Peptides
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Protein Kinase Inhibitors and by the two compound strategies of Antibodies and Peptides. Each of these three individual parts is evaluated according
|
more...
|
$5,175.00
|
|
Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Each of these three individual parts is evaluated
|
more...
|
$5,175.00
|
|
Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Each of these three individual parts is evaluated
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Triple Analysis: Leukemia, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is evaluated
|
more...
|
$5,175.00
|
